APO Research
Talk to an analyst

APO RESEARCH · REPORT

Latent Tuberculosis Infection (LTBI) Testing

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

Selected research

Market Outlook & Growth Opportunities

Global Latent Tuberculosis Infection (LTBI) Testing Market Outlook and Growth Opportunities 2026

28 December 2025199 pages

Choose your research edition.

Industry ResearchLatent Tuberculosis Infection (LTBI) Testing Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Latent Tuberculosis Infection (LTBI) Testing Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Latent Tuberculosis Infection (LTBI) Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Latent Tuberculosis Infection (LTBI) Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

Read the full market overview

The detection industry of latent tuberculosis infection (LTBI) can be subdivided into several parts: tuberculin skin test (TST), interferon release test (IGRA), etc.

Globally, there are mainly Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis infection (LTBI) is an important strategy recognized by the World Health Organization to accelerate the decline of global tuberculosis and achieve the elimination of tuberculosis. Latent tuberculosis infection (LTBI) refers to the state of continuous immune response to the stimulation of Mycobacterium tuberculosis antigen in the absence of clinical evidence of active tuberculosis (TB). The diagnosis and treatment of long-term tuberculosis is very important for tuberculosis, especially for high-risk groups. Tuberculin skin tests (TST) and interferon release tests (IGRAs) were used to diagnose LTBI.

This report provides an overview of the global Latent Tuberculosis Infection (LTBI) Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Latent Tuberculosis Infection (LTBI) Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Latent Tuberculosis Infection (LTBI) Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Latent Tuberculosis Infection (LTBI) Testing market.

Latent Tuberculosis Infection (LTBI) Testing Segment by Company

Qiagen

Sanofi

Oxford Immunotec

Thermo Fisher Scientific

Par Sterile

Bio-Rad Laboratories

Latent Tuberculosis Infection (LTBI) Testing Segment by Type

Tuberculin Skin Test (TST)

Interferon Gamma Released Assay (IGRA)

Latent Tuberculosis Infection (LTBI) Testing Segment by Application

Hospitals and Clinics

Diagnostic Laboratories

Others

Latent Tuberculosis Infection (LTBI) Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Latent Tuberculosis Infection (LTBI) Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Latent Tuberculosis Infection (LTBI) Testing key companies, revenue, market share, and recent developments.

3. To split the Latent Tuberculosis Infection (LTBI) Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Latent Tuberculosis Infection (LTBI) Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Latent Tuberculosis Infection (LTBI) Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Latent Tuberculosis Infection (LTBI) Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latent Tuberculosis Infection (LTBI) Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Latent Tuberculosis Infection (LTBI) Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latent Tuberculosis Infection (LTBI) Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Latent Tuberculosis Infection (LTBI) Testing industry.

Chapter 3: Detailed analysis of Latent Tuberculosis Infection (LTBI) Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Latent Tuberculosis Infection (LTBI) Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Latent Tuberculosis Infection (LTBI) Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Latent Tuberculosis Infection (LTBI) Testing Industry Trends Table 2. Latent Tuberculosis Infection (LTBI) Testing Industry Drivers Table 3. Latent Tuberculosis Infection (LTBI) Testing Industry Opportunities and Challenges Table 4. Latent Tuberculosis Infection (LTBI) Testing Industry Restraints Table 5. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Latent Tuberculosis Infection (LTBI) Testing Revenue Share by Company (2021-2026) Table 7. Global Latent Tuberculosis Infection (LTBI) Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Latent Tuberculosis Infection (LTBI) Testing Key Company Manufacturing Base & Headquarters Table 9. Global Latent Tuberculosis Infection (LTBI) Testing Company, Product Type & Application Table 10. Global Latent Tuberculosis Infection (LTBI) Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Latent Tuberculosis Infection (LTBI) Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tuberculin Skin Test (TST) Table 15. Significant Companies of Interferon Gamma Released Assay (IGRA) Table 16. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type (2021-2026) Table 20. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals and Clinics Table 22. Significant Companies of Diagnostic Laboratories Table 23. Significant Companies of Others Table 24. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application (2021-2026) Table 28. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application (2027-2032) Table 29. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Region (2021-2026) Table 32. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Region (2027-2032) Table 34. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Market Share by Country (2021-2026) Table 37. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Market Share by Country (2027-2032) Table 39. Qiagen Company Information Table 40. Qiagen Business Overview Table 41. Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 43. Qiagen Recent Development Table 44. Sanofi Company Information Table 45. Sanofi Business Overview Table 46. Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sanofi Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 48. Sanofi Recent Development Table 49. Oxford Immunotec Company Information Table 50. Oxford Immunotec Business Overview Table 51. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 53. Oxford Immunotec Recent Development Table 54. Thermo Fisher Scientific Company Information Table 55. Thermo Fisher Scientific Business Overview Table 56. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 58. Thermo Fisher Scientific Recent Development Table 59. Par Sterile Company Information Table 60. Par Sterile Business Overview Table 61. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 63. Par Sterile Recent Development Table 64. Bio-Rad Laboratories Company Information Table 65. Bio-Rad Laboratories Business Overview Table 66. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio Table 68. Bio-Rad Laboratories Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. Latent Tuberculosis Infection (LTBI) Testing Product Image Figure 2. Global Latent Tuberculosis Infection (LTBI) Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Latent Tuberculosis Infection (LTBI) Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Latent Tuberculosis Infection (LTBI) Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tuberculin Skin Test (TST) Image Figure 8. Interferon Gamma Released Assay (IGRA) Image Figure 9. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type (2021-2032) Figure 12. Hospitals and Clinics Image Figure 13. Diagnostic Laboratories Image Figure 14. Others Image Figure 15. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application (2021-2032) Figure 18. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032) & (US$ Million) Figure 21. North America Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032) & (US$ Million) Figure 27. South America Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Tuberculin Skin Test (TST)
  • Interferon Gamma Released Assay (IGRA)
Applications
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others
Companies covered
  • Qiagen
  • Sanofi
  • Oxford Immunotec
  • Thermo Fisher Scientific
  • Par Sterile
  • Bio-Rad Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Latent Tuberculosis Infection (LTBI) Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Latent Tuberculosis Infection (LTBI) Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Latent Tuberculosis Infection (LTBI) Testing Market Dynamics
  1. 2.1 Latent Tuberculosis Infection (LTBI) Testing Industry Trends
  2. 2.2 Latent Tuberculosis Infection (LTBI) Testing Industry Drivers
  3. 2.3 Latent Tuberculosis Infection (LTBI) Testing Industry Opportunities and Challenges
  4. 2.4 Latent Tuberculosis Infection (LTBI) Testing Industry Restraints
3 Latent Tuberculosis Infection (LTBI) Testing Market by Company
  1. 3.1 Global Latent Tuberculosis Infection (LTBI) Testing Company Revenue Ranking in 2025
  2. 3.2 Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Company (2021-2026)
  3. 3.3 Global Latent Tuberculosis Infection (LTBI) Testing Company Ranking (2024-2026)
  4. 3.4 Global Latent Tuberculosis Infection (LTBI) Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Latent Tuberculosis Infection (LTBI) Testing Company Product Type and Application
  6. 3.6 Global Latent Tuberculosis Infection (LTBI) Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Latent Tuberculosis Infection (LTBI) Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Latent Tuberculosis Infection (LTBI) Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Latent Tuberculosis Infection (LTBI) Testing Market by Type
  1. 4.1 Latent Tuberculosis Infection (LTBI) Testing Type Introduction
  2. 4.1.1 Tuberculin Skin Test (TST)
  3. 4.1.2 Interferon Gamma Released Assay (IGRA)
  4. 4.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type
  5. 4.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type (2021-2032)
5 Latent Tuberculosis Infection (LTBI) Testing Market by Application
  1. 5.1 Latent Tuberculosis Infection (LTBI) Testing Application Introduction
  2. 5.1.1 Hospitals and Clinics
  3. 5.1.2 Diagnostic Laboratories
  4. 5.1.3 Others
  5. 5.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application
  6. 5.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Application (2021-2032)
  8. 5.2.3 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application (2021-2032)
6 Latent Tuberculosis Infection (LTBI) Testing Regional Value Analysis
  1. 6.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032)
  7. 6.3.2 North America Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032)
  16. 6.6.2 South America Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Country, 2025 VS 2032
7 Latent Tuberculosis Infection (LTBI) Testing Country-level Value Analysis
  1. 7.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Latent Tuberculosis Infection (LTBI) Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Latent Tuberculosis Infection (LTBI) Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Qiagen
  2. 8.1.1 Qiagen Company Information
  3. 8.1.2 Qiagen Business Overview
  4. 8.1.3 Qiagen Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qiagen Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  6. 8.1.5 Qiagen Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Oxford Immunotec
  14. 8.3.1 Oxford Immunotec Company Information
  15. 8.3.2 Oxford Immunotec Business Overview
  16. 8.3.3 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Oxford Immunotec Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  18. 8.3.5 Oxford Immunotec Recent Developments
  19. 8.4 Thermo Fisher Scientific
  20. 8.4.1 Thermo Fisher Scientific Company Information
  21. 8.4.2 Thermo Fisher Scientific Business Overview
  22. 8.4.3 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Thermo Fisher Scientific Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  24. 8.4.5 Thermo Fisher Scientific Recent Developments
  25. 8.5 Par Sterile
  26. 8.5.1 Par Sterile Company Information
  27. 8.5.2 Par Sterile Business Overview
  28. 8.5.3 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Par Sterile Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  30. 8.5.5 Par Sterile Recent Developments
  31. 8.6 Bio-Rad Laboratories
  32. 8.6.1 Bio-Rad Laboratories Company Information
  33. 8.6.2 Bio-Rad Laboratories Business Overview
  34. 8.6.3 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Rad Laboratories Latent Tuberculosis Infection (LTBI) Testing Product Portfolio
  36. 8.6.5 Bio-Rad Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst